Viral Vector Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America & Middle East & Africa)

Description

The global market for viral vector manufacturing has witnessed remarkable growth over the past decade. In 2024, the market recorded revenue of US$ 800 million, and it is projected to reach a valuation of US$ 3000 million by the end of 2031. These insights were shared by Fairfield Market Research in their latest report on the viral vector manufacturing market.

The report reveals that adeno-associated viral vectors, securing a market value of US$ 209.6 million in 2021, have played a pivotal role in driving market growth. Viral vectors, essential tools for effective gene transfer, have become a cornerstone in gene and cell therapy, contributing significantly to the modification of specific tissues or cell types to induce therapeutic effects.

Viral vectors, both in-vitro and in-vivo, have proven instrumental in activating cellular immunity and humoral responses, making them a preferred choice for vaccines against various malignancies and infectious disorders. Additionally, the escalating demand for gene therapy due to the rising number of patients with chronic and hereditary diseases further propels the growth of viral vector manufacturing.

The World Health Organization's revelation that ten in every thousand individuals encounter some form of genetic disease underscores the urgent need for gene therapy, thereby driving the demand for viral vectors.

Key Drivers of Viral Vector Manufacturing Growth

One of the primary drivers of the escalating demand for viral vector manufacturing is its extensive use in T-cell engineering for cancer treatment. Viral vectors, particularly lentiviral vectors, have played a crucial role in the development of gene-modified cell-based therapeutics, especially T-cell therapies, which have shown clinical efficacy and safety in patients with B-cell malignancies.

Furthermore, the approval of the first genetically engineered cellular therapy by the FDA, utilizing lentiviral vectors, has paved the way for advancements in CAR T-cell therapy. This evolution is expected to contribute significantly to the viral vector manufacturing market's growth.

The report also highlights the substantial role of viral vectors in vaccine development, including the production of COVID-19 vaccines. The unique characteristics of viral vectors, such as low pathogenicity, genetic safety, and efficacy in antigen expression, position them as ideal candidates for vaccine delivery systems.

Challenges and Barriers

Despite the promising growth, viral vector manufacturing faces challenges that could impact its development. Critical factors include the selection of a suitable production system, the development of quality assays, and the optimization of downstream processing. Additionally, the high cost of gene therapies poses a potential barrier to the market's expansion over the forecast period.

Country-wise Insights

The United States remains a prominent player in the viral vector manufacturing market, accounting for 92.1% share in the North American region in 2023. The presence of key manufacturers such as ThermoFisher Scientific Inc., Waisman Biomanufacturing, and others contributes to the country's dominance in the market.

The United Kingdom, with a 22.9% share of the European market in 2023, is witnessing rapid growth due to increased research activities related to cancer treatment. Lentiviral vectors are extensively studied for T-cell engineering, contributing to the market's expansion.

China emerges as a significant market, holding the largest share of 48.2% in the East Asia market in 2023. The growth is attributed to the expansion of manufacturing units, collaborative strategic planning, and the construction of new facilities like the 34,000 square meter GMP manufacturing facility by GenScript ProBio.

Competitive Analysis

Major viral vector producers are adopting strategic alliances, product launches, and acquisitions to enhance their market presence. For instance, SIRION Biotech partnered with the Centre for Genomic Regulation to create novel adeno-associated virus vectors for type 1 and type 2 diabetic gene therapy. ThermoFisher Scientific Inc. opened a cutting-edge manufacturing facility in August 2022, further strengthening its position in the viral vector manufacturing market.

In conclusion, the global viral vector manufacturing market is poised for substantial growth, driven by advancements in gene and cell therapy, vaccine development, and increased research activities. Despite facing challenges, strategic collaborations and expansions are expected to propel the market towards new heights, with the United States, the United Kingdom, and China leading the way.

Key Companies Profiled

Thermo Fisher Scientific Inc
Charles River (Cobra Biologics)
Novasep
uniQure N.V.
Waisman Biomanufacturing
Creative Biogene
GenScript Biotech Corporation
Novartis AG
Merck KGaA.
Takara Bio Inc.
FUJIFILM Diosynth Biotechnologies
Lonza
Danaher Corp. (Aldevron)
Sirion-Biotech GmbH
AGC Biologics

Key Segments of Manufacturing of Viral Vector Industry Research

by Virus Type:

Lentiviral Vectors
Adenoviral Vectors
Adeno-Associated Viral Vectors
Retrovirus

by Expression System:

Transient
Stable

by Application:

Gene Therapy
Vaccines
Cancer Therapy
Others

by End User:

Biotechnology Companies
Pharmaceutical Companies
Contract Research Organizations (CROs)
Academic and Research Institutes

by Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa (MEA)

1. Executive Summary

1.1. Global Viral Vector Manufacturing Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Viral Vector Manufacturing Market Outlook, 2018 - 2031

3.1. Global Viral Vector Manufacturing Market Outlook, by Virus Type, Value (US$ Mn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Lentiviral Vectors
  - 3.1.1.2. Adenoviral Vectors
  - 3.1.1.3. Adeno-Associated Viral Vectors
  - 3.1.1.4. Retrovirus
3.2. Global Viral Vector Manufacturing Market Outlook, by Expression System, Value (US$ Mn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Transient
  - 3.2.1.2. Stable
3.3. Global Viral Vector Manufacturing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Gene Therapy
  - 3.3.1.2. Vaccines
  - 3.3.1.3. Cancer Therapy
  - 3.3.1.4. Others
3.4. Global Viral Vector Manufacturing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. Biotechnology Companies
  - 3.4.1.2. Pharmaceutical Companies
  - 3.4.1.3. Contract Research Organizations (CROs)
  - 3.4.1.4. Academic and Research Institutes
3.5. Global Viral Vector Manufacturing Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
- 3.5.1. Key Highlights
  - 3.5.1.1. North America
  - 3.5.1.2. Europe
  - 3.5.1.3. Asia Pacific
  - 3.5.1.4. Latin America
  - 3.5.1.5. Middle East & Africa

4. North America Viral Vector Manufacturing Market Outlook, 2018 - 2031

4.1. North America Viral Vector Manufacturing Market Outlook, by Virus Type, Value (US$ Mn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Lentiviral Vectors
  - 4.1.1.2. Adenoviral Vectors
  - 4.1.1.3. Adeno-Associated Viral Vectors
  - 4.1.1.4. Retrovirus
4.2. North America Viral Vector Manufacturing Market Outlook, by Expression System, Value (US$ Mn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Transient
  - 4.2.1.2. Stable
4.3. North America Viral Vector Manufacturing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Gene Therapy
  - 4.3.1.2. Vaccines
  - 4.3.1.3. Cancer Therapy
  - 4.3.1.4. Others
4.4. North America Viral Vector Manufacturing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. Biotechnology Companies
  - 4.4.1.2. Pharmaceutical Companies
  - 4.4.1.3. Contract Research Organizations (CROs)
  - 4.4.1.4. Academic and Research Institutes
- 4.4.2. BPS Analysis/Market Attractiveness Analysis
4.5. North America Viral Vector Manufacturing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 4.5.1. Key Highlights
  - 4.5.1.1. U.S. Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 4.5.1.2. U.S. Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 4.5.1.3. U.S. Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 4.5.1.4. U.S. Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 4.5.1.5. Canada Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 4.5.1.6. Canada Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 4.5.1.7. Canada Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 4.5.1.8. Canada Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
- 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Viral Vector Manufacturing Market Outlook, 2018 - 2031

5.1. Europe Viral Vector Manufacturing Market Outlook, by Virus Type, Value (US$ Mn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Lentiviral Vectors
  - 5.1.1.2. Adenoviral Vectors
  - 5.1.1.3. Adeno-Associated Viral Vectors
  - 5.1.1.4. Retrovirus
5.2. Europe Viral Vector Manufacturing Market Outlook, by Expression System, Value (US$ Mn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Transient
  - 5.2.1.2. Stable
5.3. Europe Viral Vector Manufacturing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Gene Therapy
  - 5.3.1.2. Vaccines
  - 5.3.1.3. Cancer Therapy
  - 5.3.1.4. Others
5.4. Europe Viral Vector Manufacturing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Biotechnology Companies
  - 5.4.1.2. Pharmaceutical Companies
  - 5.4.1.3. Contract Research Organizations (CROs)
  - 5.4.1.4. Academic and Research Institutes
- 5.4.2. BPS Analysis/Market Attractiveness Analysis
5.5. Europe Viral Vector Manufacturing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 5.5.1. Key Highlights
  - 5.5.1.1. Germany Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 5.5.1.2. Germany Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 5.5.1.3. Germany Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 5.5.1.4. Germany Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.5.1.5. U.K. Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 5.5.1.6. U.K. Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 5.5.1.7. U.K. Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 5.5.1.8. U.K. Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.5.1.9. France Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 5.5.1.10. France Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 5.5.1.11. France Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 5.5.1.12. France Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.5.1.13. Italy Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 5.5.1.14. Italy Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 5.5.1.15. Italy Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 5.5.1.16. Italy Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.5.1.17. Turkey Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 5.5.1.18. Turkey Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 5.5.1.19. Turkey Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 5.5.1.20. Turkey Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.5.1.21. Russia Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 5.5.1.22. Russia Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 5.5.1.23. Russia Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 5.5.1.24. Russia Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.5.1.25. Rest of Europe Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 5.5.1.26. Rest of Europe Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 5.5.1.27. Rest of Europe Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 5.5.1.28. Rest of Europe Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
- 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Viral Vector Manufacturing Market Outlook, 2018 - 2031

6.1. Asia Pacific Viral Vector Manufacturing Market Outlook, by Virus Type, Value (US$ Mn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Lentiviral Vectors
  - 6.1.1.2. Adenoviral Vectors
  - 6.1.1.3. Adeno-Associated Viral Vectors
  - 6.1.1.4. Retrovirus
6.2. Asia Pacific Viral Vector Manufacturing Market Outlook, by Expression System, Value (US$ Mn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Transient
  - 6.2.1.2. Stable
6.3. Asia Pacific Viral Vector Manufacturing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Gene Therapy
  - 6.3.1.2. Vaccines
  - 6.3.1.3. Cancer Therapy
  - 6.3.1.4. Others
6.4. Asia Pacific Viral Vector Manufacturing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. Biotechnology Companies
  - 6.4.1.2. Pharmaceutical Companies
  - 6.4.1.3. Contract Research Organizations (CROs)
  - 6.4.1.4. Academic and Research Institutes
- 6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. Asia Pacific Viral Vector Manufacturing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 6.5.1. Key Highlights
  - 6.5.1.1. China Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 6.5.1.2. China Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 6.5.1.3. China Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 6.5.1.4. China Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.5.1.5. Japan Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 6.5.1.6. Japan Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 6.5.1.7. Japan Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 6.5.1.8. Japan Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.5.1.9. South Korea Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 6.5.1.10. South Korea Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 6.5.1.11. South Korea Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 6.5.1.12. South Korea Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.5.1.13. India Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 6.5.1.14. India Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 6.5.1.15. India Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 6.5.1.16. India Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.5.1.17. Southeast Asia Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 6.5.1.18. Southeast Asia Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 6.5.1.19. Southeast Asia Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 6.5.1.20. Southeast Asia Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.5.1.21. Rest of Asia Pacific Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 6.5.1.22. Rest of Asia Pacific Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 6.5.1.23. Rest of Asia Pacific Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 6.5.1.24. Rest of Asia Pacific Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
- 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Viral Vector Manufacturing Market Outlook, 2018 - 2031

7.1. Latin America Viral Vector Manufacturing Market Outlook, by Virus Type, Value (US$ Mn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Lentiviral Vectors
  - 7.1.1.2. Adenoviral Vectors
  - 7.1.1.3. Adeno-Associated Viral Vectors
  - 7.1.1.4. Retrovirus
7.2. Latin America Viral Vector Manufacturing Market Outlook, by Expression System, Value (US$ Mn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Transient
  - 7.2.1.2. Stable
7.3. Latin America Viral Vector Manufacturing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Gene Therapy
  - 7.3.1.2. Vaccines
  - 7.3.1.3. Cancer Therapy
  - 7.3.1.4. Others
7.4. Latin America Viral Vector Manufacturing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Biotechnology Companies
  - 7.4.1.2. Pharmaceutical Companies
  - 7.4.1.3. Contract Research Organizations (CROs)
  - 7.4.1.4. Academic and Research Institutes
- 7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Latin America Viral Vector Manufacturing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 7.5.1. Key Highlights
  - 7.5.1.1. Brazil Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 7.5.1.2. Brazil Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 7.5.1.3. Brazil Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 7.5.1.4. Brazil Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 7.5.1.5. Mexico Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 7.5.1.6. Mexico Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 7.5.1.7. Mexico Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 7.5.1.8. Mexico Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 7.5.1.9. Argentina Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 7.5.1.10. Argentina Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 7.5.1.11. Argentina Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 7.5.1.12. Argentina Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 7.5.1.13. Rest of Latin America Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 7.5.1.14. Rest of Latin America Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 7.5.1.15. Rest of Latin America Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 7.5.1.16. Rest of Latin America Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
- 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Viral Vector Manufacturing Market Outlook, 2018 - 2031

8.1. Middle East & Africa Viral Vector Manufacturing Market Outlook, by Virus Type, Value (US$ Mn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Lentiviral Vectors
  - 8.1.1.2. Adenoviral Vectors
  - 8.1.1.3. Adeno-Associated Viral Vectors
  - 8.1.1.4. Retrovirus
8.2. Middle East & Africa Viral Vector Manufacturing Market Outlook, by Expression System, Value (US$ Mn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Transient
  - 8.2.1.2. Stable
8.3. Middle East & Africa Viral Vector Manufacturing Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Gene Therapy
  - 8.3.1.2. Vaccines
  - 8.3.1.3. Cancer Therapy
  - 8.3.1.4. Others
8.4. Middle East & Africa Viral Vector Manufacturing Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. Biotechnology Companies
  - 8.4.1.2. Pharmaceutical Companies
  - 8.4.1.3. Contract Research Organizations (CROs)
  - 8.4.1.4. Academic and Research Institutes
- 8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Middle East & Africa Viral Vector Manufacturing Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 8.5.1. Key Highlights
  - 8.5.1.1. GCC Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 8.5.1.2. GCC Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 8.5.1.3. GCC Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 8.5.1.4. GCC Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 8.5.1.5. South Africa Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 8.5.1.6. South Africa Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 8.5.1.7. South Africa Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 8.5.1.8. South Africa Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 8.5.1.9. Egypt Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 8.5.1.10. Egypt Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 8.5.1.11. Egypt Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 8.5.1.12. Egypt Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 8.5.1.13. Nigeria Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 8.5.1.14. Nigeria Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 8.5.1.15. Nigeria Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 8.5.1.16. Nigeria Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
  - 8.5.1.17. Rest of Middle East & Africa Viral Vector Manufacturing Market by Virus Type, Value (US$ Mn), 2018 - 2031
  - 8.5.1.18. Rest of Middle East & Africa Viral Vector Manufacturing Market by Expression System, Value (US$ Mn), 2018 - 2031
  - 8.5.1.19. Rest of Middle East & Africa Viral Vector Manufacturing Market by Application, Value (US$ Mn), 2018 - 2031
  - 8.5.1.20. Rest of Middle East & Africa Viral Vector Manufacturing Market by End User, Value (US$ Mn), 2018 - 2031
- 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Virus Type vs Application Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Thermo Fisher Scientific Inc
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Charles River (Cobra Biologics)
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. NOVASEP
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. uniQure N.V
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Waisman Biomanufacturing
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Creative Biogene
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. GenScript Biotech Corporation
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Novartis AG
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Merck KGaA
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Takara Bio, Inc.
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. FUJIFILM Diosynth Biotechnologies
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Product Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development
- 9.4.12. LONZA
  - 9.4.12.1. Company Overview
  - 9.4.12.2. Product Portfolio
  - 9.4.12.3. Financial Overview
  - 9.4.12.4. Business Strategies and Development
- 9.4.13. Danaher Corp. (Aldevron)
  - 9.4.13.1. Company Overview
  - 9.4.13.2. Product Portfolio
  - 9.4.13.3. Financial Overview
  - 9.4.13.4. Business Strategies and Development
- 9.4.14. Sirion Biotech GmbH
  - 9.4.14.1. Company Overview
  - 9.4.14.2. Product Portfolio
  - 9.4.14.3. Financial Overview
  - 9.4.14.4. Business Strategies and Development
- 9.4.15. AGC Biologics
  - 9.4.15.1. Company Overview
  - 9.4.15.2. Product Portfolio
  - 9.4.15.3. Financial Overview
  - 9.4.15.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations